Vertex Pharmaceuticals: A Look At Their Pain Therapy Program
Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...
Investing Snacks2d
Vertex Dodges Market Mayhem With a Wink
Despite a market bloodbath that left the S&P 500 down 4.84%, Vertex Pharmaceuticals managed a modest gain of 0.11%, flaunting resilience. The biotech firm outpaced the broader medical sector over the ...
Zacks Investment Research on MSN2d
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same time, ...
Wells Fargo Remains a Hold on Vertex Pharmaceuticals (VRTX)
Wells Fargo analyst Mohit Bansal maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target ...